Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tofersen in Amyotrophic Lateral Sclerosis 1: NCT07223723 Clinical Landscape Report 2026
18 September 2026
NCT07223723 clinical landscape for Amyotrophic Lateral Sclerosis 1: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Diffuse midline glioma, point mutation K27M in histone H3: NCT07223034 Clinical Landscape Report 2026
18 September 2026
NCT07223034 clinical landscape for Diffuse midline glioma, point mutation K27M in histone H3: endpoints, sponsor, phase, geography, readouts, asset context a…
9 min read
Tafasitamab-Cxix in High grade B-cell lymphoma: NCT07225439 Clinical Landscape Report 2026
18 September 2026
NCT07225439 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
177Lu-FAPI in Glioblastoma: CTRI/2025/11/097005 Clinical Landscape Report 2026
18 September 2026
CTRI/2025/11/097005 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cemiplimab-RWLC in Metastatic Clear Cell Renal Cell Carcinoma: NCT07223541 Clinical Landscape Report 2026
18 September 2026
NCT07223541 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Navlimetostat in Glioblastoma Multiforme: ACTRN12625001238460 Clinical Landscape Report 2026
18 September 2026
ACTRN12625001238460 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in Renal Cell Carcinoma: NCT07226544 Clinical Landscape Report 2026
18 September 2026
NCT07226544 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Polatuzumab Vedotin-Piiq in ALK positive large B-cell lymphoma: NCT07231250 Clinical Landscape Report 2026
18 September 2026
NCT07231250 clinical landscape for ALK positive large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Fludarabine Phosphate in Osteosarcoma, Recurrent: NCT07227571 Clinical Landscape Report 2026
18 September 2026
NCT07227571 clinical landscape for Osteosarcoma, Recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Belzutifan in Renal Cell Carcinoma: NCT07227402 Clinical Landscape Report 2026
18 September 2026
NCT07227402 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LY-4584180 in Follicular Lymphoma: NCT07226843 Clinical Landscape Report 2026
18 September 2026
NCT07226843 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Metastatic Renal Cell Carcinoma: NCT07227415 Clinical Landscape Report 2026
18 September 2026
NCT07227415 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.